Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MUSE: PK and Safety of ARQ-151 Cream in Psoriasis
NCT04279119Phase 1Completed
- Sponsor
- Arcutis Biotherapeutics
- Start
- Mar 2020
- Primary completion
- Mar 2021
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of roflumilast vehicle cream in plaque psoriasis, sponsored by Arcutis Biotherapeutics. Primary endpoints: Maximum Plasma Concentration at 5 weeks, Area Under the Curve at 5 weeks and 1 more. Started Mar 2020; status: completed.
02
Drugs
roflumilast vehicle cream
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04279119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04279119.